A pharma bailout?

Paul, Reid
March 2009
Pharmaceutical Representative;Mar2009, Vol. 39 Issue 3, p3
The author reflects on government bailouts for pharmaceutical companies in the U.S. He notes that pharmaceutical companies are suffering for they shed jobs especially in the pharmaceutical representative sector. Accordingly, he argues that bailout would make sense in terms of job security. He mentions a report from Stockholm Network asserting that the lack of government investment was preventing the industry in Great Britain and pressures the government to do so.


Related Articles

  • CORRESPONDENCE. McCaughey, Elizabeth; Klausen, Jytte; Wolfe, Alan; Twiss, Elizabeth; Deconcini, Barbara; St. Clair, Marshall; Mitchell, Anne P.; Adler, David R. // New Republic;5/22/95, Vol. 212 Issue 21, p6 

    Presents letters to the editor referencing articles and topics discussed in previous issues. "No Exegesis," which focused on the health bill proposed by U.S. President Bill Clinton; "Invasion of the Church Ladies," which discussed the issue of abortion; "Let Them Eat Hate," which focused on the...

  • New Study Says GM Bailout Spared 1.2 Million Jobs.  // Chicago Citizen - Chatham Southeast Edition;1/15/2014, Vol. 48 Issue 43, p4 

    The article focuses on a study by researchers of the Center for Automotive Research Sean McAlinden and Debra Maranger Menk as of 2014, according to which the bailout of General Motors Co. by the U.S. government spared 1.2 million jobs in 2009 and preserved 39.4 billion dollars in tax collections.

  • Erratum.  // Pharmaceutical Executive;Mar2013, Vol. 33 Issue 3, pS16 

    A correction to the article about the economic aspects of the pharmaceutical industry in Singapore that was published in the January 2013 issue is presented.

  • R.Ph.s prefer peer review of pharmacoeconomic data. Gebhart, Fred // Drug Topics;7/8/96, Vol. 140 Issue 13, p28 

    Reports that managed care organizations (MCO) pharmacy directors want outside help to assess the cost-effectiveness of new drugs and drug technologies in the United States. Use of technology assessment; Issues about industry-sponsored cost-effectiveness studies; Improving manage costs and...

  • EE.UU. y otra encrucijada: ¿cuándo desactivar la intervención estatal? Petersen, Andrés Gil // Revista de Antiguos Alumnos del IEEM;2009, Vol. 12 Issue 4, p26 

    No abstract available.

  • readers talk.  // DRIP Investor;Jun2000, Vol. 9 Issue 6, p3 

    Reports business developments on pharmaceutical industry. Characteristics of traditional drug stocks and biotechnology stocks; Role of biotechnology in health-care investments; Contact information of Pfizer for DRIP investment program.

  • Pharma growth slows in wake of global recession. Mirasol, Feliza // Chemical Market Reporter;09/21/98, Vol. 254 Issue 12, p4 

    Discusses the effect of economic slowdowns and healthcare pressures on the growth of global pharmaceutical companies. Challenges in the European, Latin American and Asian markets; Stability of the industry in North America; Projection of sales based on past trends.

  • Comparable-store sales performance.  // Drug Store News;4/26/99, Vol. 21 Issue 7, p56 

    Focuses on the comparable-store sales performance of drug store chains in the United States in 1998. Increase in the comparable-store sales of drug chains; Details on the companies which topped the lists in 1998.

  • Tax 'Excessive' Pharma Profits. Lee, Joel // H&HN: Hospitals & Health Networks;Sep2014, Vol. 88 Issue 9, p16 

    A letter to the editor in response to the article "Prescription Drug Costs and the Specter of Rationing," by Emily Friedman in the August 5, 2014 issue is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics